BRPI0415277A - célula, vetor, método para produzir proteìna gama-carboxilada, proteìna gama-carboxilada isolada, uso da mesma, método para produzir uma composição farmacêutica, composição farmacêutica, método para produzir fator x de humano gama-carboxilado, uso de fator x isolado, método para produzir protrombina de humano gama-carboxilada, uso de protrombina isolada, e, método para promover coagulação aumentada ou diminuìda em um indivìduo - Google Patents

célula, vetor, método para produzir proteìna gama-carboxilada, proteìna gama-carboxilada isolada, uso da mesma, método para produzir uma composição farmacêutica, composição farmacêutica, método para produzir fator x de humano gama-carboxilado, uso de fator x isolado, método para produzir protrombina de humano gama-carboxilada, uso de protrombina isolada, e, método para promover coagulação aumentada ou diminuìda em um indivìduo

Info

Publication number
BRPI0415277A
BRPI0415277A BRPI0415277-8A BRPI0415277A BRPI0415277A BR PI0415277 A BRPI0415277 A BR PI0415277A BR PI0415277 A BRPI0415277 A BR PI0415277A BR PI0415277 A BRPI0415277 A BR PI0415277A
Authority
BR
Brazil
Prior art keywords
isolated
gamma carboxylated
producing
protein
pharmaceutical composition
Prior art date
Application number
BRPI0415277-8A
Other languages
English (en)
Inventor
Christel Fenge
Ann Loevgren
Andrers Thelin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29559260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0415277(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0415277A publication Critical patent/BRPI0415277A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

"CéLULA, VETOR, MéTODO PAPA PRODUZIR PROTEìNA GAMACARBOXILADA, PROTEìNA GAMA-CARBOXILADA ISULADA, USO DA MESMA, MéTODO PARA PRODUZIR UMA COMPOSIçãO FARMACêUTICA, COMPOSIçãO FARMACêUTICA, MéTODO PARA PRODUZIR FATOR X DE HUMANO GAMA-CARBOXILADO, USO DE FATOR X ISOLADO, MéTODO PARA PRODUZIR PROTROMBINA DE HUMANO GAMA-CARBOXILADA, USO DE PROTROMBINA ISOLADA, E, MéTODO PARA PROMOVER COAGULAçãO AUMENTADA OU DIMINUìDA EM UM INDIVìDUO". A presente invenção refere-se aos métodos e às ferramentas para produzir quantidades grandes de proteina gama-carboxilada compreendendo: (i) cultivar uma célula adaptada para expressar uma proteína que requer gama-carboxilação e <sym>-glutamil-carboxilase em uma razão de pelo menos 10:1, sob condições adequadas para a expressão de ambas proteínas; e (ii) isolar a proteína gama-carboxilada.
BRPI0415277-8A 2003-10-14 2004-10-12 célula, vetor, método para produzir proteìna gama-carboxilada, proteìna gama-carboxilada isolada, uso da mesma, método para produzir uma composição farmacêutica, composição farmacêutica, método para produzir fator x de humano gama-carboxilado, uso de fator x isolado, método para produzir protrombina de humano gama-carboxilada, uso de protrombina isolada, e, método para promover coagulação aumentada ou diminuìda em um indivìduo BRPI0415277A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0324044.7A GB0324044D0 (en) 2003-10-14 2003-10-14 Protein
PCT/SE2004/001453 WO2005038019A1 (en) 2003-10-14 2004-10-12 Method for producing gamma-carboxylated proteins

Publications (1)

Publication Number Publication Date
BRPI0415277A true BRPI0415277A (pt) 2006-12-19

Family

ID=29559260

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415277-8A BRPI0415277A (pt) 2003-10-14 2004-10-12 célula, vetor, método para produzir proteìna gama-carboxilada, proteìna gama-carboxilada isolada, uso da mesma, método para produzir uma composição farmacêutica, composição farmacêutica, método para produzir fator x de humano gama-carboxilado, uso de fator x isolado, método para produzir protrombina de humano gama-carboxilada, uso de protrombina isolada, e, método para promover coagulação aumentada ou diminuìda em um indivìduo

Country Status (29)

Country Link
US (2) US7842477B2 (pt)
EP (2) EP2292748B1 (pt)
JP (1) JP4658946B2 (pt)
KR (1) KR101201020B1 (pt)
CN (2) CN1867669B (pt)
AR (1) AR046180A1 (pt)
AT (1) ATE491789T1 (pt)
AU (2) AU2004281350B2 (pt)
BR (1) BRPI0415277A (pt)
CA (1) CA2541764C (pt)
CO (1) CO5690657A2 (pt)
DE (1) DE602004030603D1 (pt)
DK (1) DK1678297T3 (pt)
ES (2) ES2357603T3 (pt)
GB (1) GB0324044D0 (pt)
HK (1) HK1155475A1 (pt)
IL (2) IL174633A (pt)
IS (1) IS8447A (pt)
MX (1) MXPA06004060A (pt)
MY (1) MY141859A (pt)
NO (1) NO339740B1 (pt)
NZ (2) NZ578306A (pt)
PL (1) PL1678297T3 (pt)
PT (1) PT1678297E (pt)
RU (2) RU2372401C2 (pt)
TW (1) TWI355419B (pt)
UY (1) UY28558A1 (pt)
WO (1) WO2005038019A1 (pt)
ZA (1) ZA200603038B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004275828B2 (en) 2003-09-23 2010-04-29 University Of North Carolina At Chapel Hill Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin K epoxide reductase gene and warfarin dosage
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
JP2008532544A (ja) 2005-03-15 2008-08-21 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 活性ビタミンｋ依存性タンパク質を生産するための方法及び組成物
CN101198696B (zh) * 2005-04-13 2014-02-26 阿斯利康(瑞典)有限公司 包含产生需要γ-羧化的蛋白质用的载体的宿主细胞
AU2006298160A1 (en) * 2005-09-30 2007-04-12 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Process for preparing recombinant human thrombin with culture cell
US7745484B2 (en) 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
PL1969127T5 (pl) * 2005-12-21 2018-02-28 Cnj Holdings, Inc Metoda wytwarzania biologicznie czynnych białek zależnych od witaminy K metodami rekombinacji
EP2407561A3 (en) * 2006-03-06 2012-05-30 Humagene, Inc. A method for the preparation of recombinant human fibrinogen
EP2517714A1 (en) * 2007-04-26 2012-10-31 Inspiration Biopharmaceuticals, Inc. Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
US8206967B2 (en) * 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin
EP2624859B1 (en) 2010-10-06 2017-03-01 Medimmune Limited Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy
EP2655607A4 (en) 2010-12-21 2014-05-14 Univ North Carolina METHOD AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS
WO2013036445A1 (en) * 2011-09-06 2013-03-14 Medimmune Llc Methods for processing coagulation factors
RU2500816C1 (ru) * 2012-07-19 2013-12-10 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК рАК380, КОДИРУЮЩАЯ ПОЛИПЕПТИД РЕКОМБИНАНТНОГО ФАКТОРА IХ СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА, ЛИНИЯ КЛЕТОК Cricetulus griseus CHO 1E6 - ПРОДУЦЕНТ РЕКОМБИНАНТНОГО ФАКТОРА IХ СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА И СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА, ОБЛАДАЮЩЕГО АКТИВНОСТЬЮ РЕКОМБИНАНТНОГО ФАКТОРА IХ
JP5830486B2 (ja) 2013-03-29 2015-12-09 シスメックス株式会社 組換えバキュロウイルスおよびその利用
ES2758505T3 (es) * 2013-12-20 2020-05-05 Novartis Ag Células eucariotas novedosas y métodos para expresar de forma recombinante un producto de interés
CN109207462B (zh) * 2018-08-01 2021-05-11 深圳市新产业生物医学工程股份有限公司 异常凝血酶原及其制备方法和包含其的检测剂、试剂盒及应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3043857A1 (de) 1980-11-21 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ii und vii
US4599308A (en) * 1981-10-06 1986-07-08 Hamer Dean H Protein from SV40 recombinants
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
JPH01502080A (ja) 1986-11-17 1989-07-27 ニュー・イングランド・メディカル・センター 組み換えビタミンｋ依存性蛋白質のガンマカルボキシル化の増強
US6224864B1 (en) 1986-12-03 2001-05-01 Pharmacia & Upjohn Company Antibiotic 10381A, and process for the preparation of anitbiotics 10381B
JPH03501921A (ja) 1987-05-18 1991-05-09 インテグレイテッド・ジェネティクス・インク 改良タンパク質分子、並びにその製造及び活性化方法
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
CA1330302C (en) 1988-01-18 1994-06-21 Miroslav Rybak Concentrates of coagulation factors ii, vii, ix and x, method of their preparation and use
WO1992001795A1 (en) 1990-07-23 1992-02-06 Zymogenetics, Inc. Gamma-carboxylase and methods of use
US5965789A (en) 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
US5268275A (en) 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
US5219995A (en) 1992-07-14 1993-06-15 Alpha Therapeutic Corporation Plasma fraction purification
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5639661A (en) * 1994-03-23 1997-06-17 The University Of Iowa Research Foundation Genes and proteins for treating cystic fibrosis
DE4430204A1 (de) 1994-08-26 1996-02-29 Behringwerke Ag Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung
DE59712322D1 (de) 1996-03-20 2005-06-30 Baxter Ag Pharmazeutisches Präparat zur Behandlung von Blutgerinnungsstörungen
ATE455552T1 (de) * 1997-02-14 2010-02-15 American Nat Red Cross Expression des active human factor ix im brustdrüsengewebe transgener tiere
CA2315879A1 (en) 1997-12-24 1999-07-08 Immunex Corporation V201 dna and polypeptides
WO2001004146A2 (en) 1999-07-09 2001-01-18 Cohesion Technologies, Inc. Ecarin polypeptides, polynucleotides encoding ecarin, and methods for use thereof
AU6366100A (en) 1999-07-23 2001-02-13 Case Western Reserve University Novel methods and reagents for the treatment of osteoarthritis
US20020106381A1 (en) * 2000-06-13 2002-08-08 High Katherine A. Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus
WO2002029045A2 (en) 2000-10-02 2002-04-11 Novo Nordisk A/S Method for the production of vitamin k-dependent proteins
EP1405912B8 (en) 2001-07-06 2012-10-24 The Chemo-Sero-Therapeutic Research Institute Genetically modified ecarin and process for producing the same
ATE423199T1 (de) 2001-07-06 2009-03-15 Chemo Sero Therapeut Res Inst Verfahren zur herstelllung von menschlichem thrombin mittels genmodifikationstechnik
KR101067400B1 (ko) 2001-07-10 2011-09-27 잇판자이단호진 가가쿠오요비겟세이료호겐쿠쇼 약제학적으로 안정한 지혈용 조성물
AU2004275828B2 (en) 2003-09-23 2010-04-29 University Of North Carolina At Chapel Hill Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin K epoxide reductase gene and warfarin dosage
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
CA2542017A1 (en) 2003-10-14 2005-05-06 Baxter International, Inc. Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives
EP1676911B1 (en) 2003-10-24 2010-04-21 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Novel recombinant animal cells with high protein production, method of constructing the same and method of mass protein production using the same
WO2006067116A1 (en) 2004-12-21 2006-06-29 Novo Nordisk Health Care Ag Expression of gamma-carboxylated polypeptides in gamma-carboxylation deficient host systems
CN101198696B (zh) 2005-04-13 2014-02-26 阿斯利康(瑞典)有限公司 包含产生需要γ-羧化的蛋白质用的载体的宿主细胞
WO2007065173A2 (en) 2005-12-02 2007-06-07 Wake Forest University Health Sciences Compositions and methods for increasing production of recombinant gamma-carboxylated proteins
PL1969127T5 (pl) 2005-12-21 2018-02-28 Cnj Holdings, Inc Metoda wytwarzania biologicznie czynnych białek zależnych od witaminy K metodami rekombinacji
US8206967B2 (en) 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin

Also Published As

Publication number Publication date
EP2292748A1 (en) 2011-03-09
HK1155475A1 (en) 2012-05-18
RU2009123931A (ru) 2010-12-27
RU2006110147A (ru) 2007-11-20
US20050164367A1 (en) 2005-07-28
ATE491789T1 (de) 2011-01-15
EP2292748B1 (en) 2014-12-17
PL1678297T3 (pl) 2011-11-30
JP2007508820A (ja) 2007-04-12
GB0324044D0 (en) 2003-11-19
IS8447A (is) 2006-05-10
AU2008205445A1 (en) 2008-09-04
MXPA06004060A (es) 2006-06-28
KR101201020B1 (ko) 2012-11-14
US8697440B2 (en) 2014-04-15
TW200523365A (en) 2005-07-16
EP1678297B1 (en) 2010-12-15
AR046180A1 (es) 2005-11-30
NO20061470L (no) 2006-05-12
PT1678297E (pt) 2011-03-15
CA2541764A1 (en) 2005-04-28
US20110092429A1 (en) 2011-04-21
CN1867669A (zh) 2006-11-22
NZ578306A (en) 2011-02-25
AU2004281350A1 (en) 2005-04-28
TWI355419B (en) 2012-01-01
IL174633A0 (en) 2006-08-20
US7842477B2 (en) 2010-11-30
UY28558A1 (es) 2005-05-31
NZ546584A (en) 2009-08-28
NO339740B1 (no) 2017-01-30
IL174633A (en) 2013-06-27
EP1678297A1 (en) 2006-07-12
CN102443548B (zh) 2014-03-12
DE602004030603D1 (de) 2011-01-27
ES2357603T3 (es) 2011-04-28
DK1678297T3 (da) 2011-03-14
JP4658946B2 (ja) 2011-03-23
WO2005038019A1 (en) 2005-04-28
ES2532470T3 (es) 2015-03-27
KR20060123152A (ko) 2006-12-01
ZA200603038B (en) 2007-09-26
MY141859A (en) 2010-07-16
IL226313A0 (en) 2013-06-27
RU2372401C2 (ru) 2009-11-10
CA2541764C (en) 2015-03-31
CN102443548A (zh) 2012-05-09
CN1867669B (zh) 2011-10-19
AU2004281350B2 (en) 2008-05-15
CO5690657A2 (es) 2006-10-31

Similar Documents

Publication Publication Date Title
BRPI0415277A (pt) célula, vetor, método para produzir proteìna gama-carboxilada, proteìna gama-carboxilada isolada, uso da mesma, método para produzir uma composição farmacêutica, composição farmacêutica, método para produzir fator x de humano gama-carboxilado, uso de fator x isolado, método para produzir protrombina de humano gama-carboxilada, uso de protrombina isolada, e, método para promover coagulação aumentada ou diminuìda em um indivìduo
BRPI0514411B8 (pt) formulação, e, método de produzir uma formulação
ATE541934T1 (de) Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon
NO20043245L (no) Bindingsproteiner som biosensorer
BRPI0620125A8 (pt) método para regulação de redução da função biológica de uma proteína, molécula de ocorrência não natural, vetor recombinante, e método para isolar uma protéina de uma amostra
CY1114701T1 (el) Συνθεσεις και μεθοδοι για αυξηση ασβεστοποιησης οστων
EP1687283A4 (en) PROCESS AND COMPOSITION FOR DETERMINING FK 506
BR0105603A (pt) Sistema e método de informação para piloto, atuado por olhar fixo sem mostrador visual
BRPI0315652B8 (pt) molécula de ácido nucleico isolada, vetor, polipeptídeo de fusão, e, multímero
ATE485331T1 (de) Thiolselektive wasserlösliche polymerderivate
BR0213207A (pt) remodelagem e glicoconjugação de peptìdeos
BRPI0910821A8 (pt) Método para modificar uma proteína, alimento, preparação de enzima para modificar uma proteína, e, método para estabelecer uma relação ótima de proteína glutaminase para transglutaminase
BR112012013330A2 (pt) composições e métodos para aumentar meia vida do soro de proteínas de fusão fc
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
AR051523A1 (es) Metodo para medir la resistencia o sensibilidad a docetaxel
BRPI0413644A (pt) métodos para separar as duas formas de um polipeptìdeo tendo uma única racemização de aminoácido, e para separar dois polipeptìdeos, produto de polipeptìdeo, e, composição farmacêutica
BRPI0810130A8 (pt) Composição de bebida, processo para produzir uma composição de bebida, e, uso de uma composição de bebida
BR0312521A (pt) Métodos para a separação e a purificação de fibrinogênio e de pelo menos uma outra proteìna e para a co-purificação de fibrinogênio e de fator xiii, uso de cromatografia de afinidade com ìon de metal imobilizado, fibrinogênio, kit farmacêutico, e, formulações farmacêutica e de fibrinogênio liofilizado
ATE466080T1 (de) Formulierungen und verfahren zum denaturieren von proteinen
NO20030495L (no) Peptider som presenteres av celler
BR0315178A (pt) Eritropoietina: remodelagem e glicoconjugação de eritropoietina
BR0210905A (pt) Anticorpos especìficos para cd44v6
IL162568A (en) Isolated nucleic acid encoding a fluorescent mutant of an aequorea coerulescens protein
BR112022000847A2 (pt) Método para inativação viral
BR0312197A (pt) Polissacarìdeo supersulfatado de baixo peso molecular

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C12N 9/64

Ipc: C12N 9/64 (2006.01), C12N 9/74 (2006.01), C12P 21/

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2483 DE 07-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.